{"id":"W2914527787","doi":"10.1016/j.jaip.2019.01.021","title":"Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study","year":2019,"lang":"en","type":"article","venue":"The Journal of Allergy and Clinical Immunology In Practice","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Allergy Research Corporation; University of Ottawa","funders":"Swedish Orphan Biovitrum; BioCryst; Genentech; Valeant Pharmaceuticals International; Regeneron Pharmaceuticals; Alnylam Pharmaceuticals; North Carolina GlaxoSmithKline Foundation; 3M; Roche; Sanofi; Merck; GlaxoSmithKline; Galderma; Aimmune Therapeutics; CSL Behring; Shire; AstraZeneca; Teva Pharmaceutical Industries; Novartis; Pfizer","keywords":"Medicine; C1-inhibitor; Prophylactic treatment; Randomized controlled trial; Surgery; Internal medicine; Angioedema","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002651794,0.001141465,0.003928533,0.0005204543,0.0005047045,0.001051301,0.0009792472,0.001611828,0.01207141],"category_scores_gemma":[0.002587121,0.0007601108,0.002125821,0.0007464869,0.001072617,0.0008243718,0.0005361468,0.001984868,0.001165079],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008095117,"about_ca_system_score_gemma":0.001553729,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0016891,"about_ca_topic_score_gemma":0.003686616,"domain_scores_codex":[0.9980872,0.001262953,0.0001104661,0.0001998064,0.0001494142,0.0001902447],"domain_scores_gemma":[0.9987489,0.0004093413,0.0003146794,0.00008884656,0.0001302445,0.00030801],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9778119,0.002924731,0.0009910016,0.001299547,0.002148707,0.00005342613,0.0000399912,0.000131083,0.000854426,0.0001372023,0.0009394175,0.0126686],"study_design_scores_gemma":[0.9741683,0.02176698,0.002122359,0.00008336444,0.0008342488,0.00003061578,0.00001766279,0.00009513529,0.00008293939,0.00006995122,0.0007197932,0.000008677731],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9413353,0.03472297,0.001444927,0.001615611,0.001428345,0.009408843,0.003537023,0.0001471906,0.006359727],"genre_scores_gemma":[0.974597,0.009788266,0.002303539,0.001808572,0.0008710212,0.005734594,0.001775585,0.00002740145,0.00309399],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01207141,"threshold_uncertainty_score":0.04038286,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02436057409019687,"score_gpt":0.3563028979809519,"score_spread":0.331942323890755,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}